関節内補充療法の市場規模：製品タイプ、材料タイプ、用途、エンドユーザー、流通チャネル、地域別、2024年～2031年

関節内補充療法市場の評価、2024年～2031年

関節内補充療法市場は、変形性関節症やその他の関節障害の有病率の上昇により拡大しています。ヒアルロン酸ベースの製品における技術革新が需要を牽引しており、ヘルスケアプロバイダーは痛みの緩和や関節機能の改善のためにこれらの治療を採用する傾向が強まっています。このため、市場規模は2024年に65億米ドルを突破し、2031年には約123億8,000万米ドルに達する見込みです。

加えて、高齢化社会の拡大により、手術以外の選択肢に対するニーズも高まっています。さらに、低侵襲治療としての関節内補充療法に対する認知度の高まりが、従来の関節手術に代わる治療法を求める患者の間で人気を集めています。関節内補充療法に対する需要の高まりにより、同市場は2024年から2031年にかけてCAGR9.24%で成長する見込みです。

定義／概要

関節内補充療法は、関節にヒアルロン酸を注入し、潤滑性とクッション性を高める治療法です。主に変形性関節症患者の疼痛管理と可動性の改善に用いられます。

滑液を増加させることで、特に膝の関節痛を緩和することに重点を置いて使用されます。この非外科的な選択肢は、中程度の関節炎症例の管理にますます人気が高まっており、普及の原動力となっています。

将来の展望には、ヒアルロン酸製剤の進歩がますます進み、より良い結果をもたらすことが含まれています。高齢化社会と非侵襲的治療への需要の高まりが、関節内補充療法の市場拡大の可能性に寄与しています。

サンプルダウンロード

変形性関節症の有病率の増加はどのように関節内補充療法市場の成長を促進しているか？

変形性関節症の有病率の増加は、効果的な疼痛管理ソリューションに対するより高い需要を生み出すことにより、関節内補充療法市場の成長を著しく促進します。関節痛の緩和や運動能力の向上を求める人が増えるにつれ、ヘルスケアプロバイダーは関節内補充療法を採用することが増えています。このような低侵襲性の選択肢は、外科的介入に代わる実行可能な選択肢を提供し、効果的でありながら侵襲性の低いアプローチを求める患者にアピールします。その結果、この動向が市場全体の拡大を支えています。

関節内補充療法の高コストは市場成長の課題か？

関節内補充療法の高額な費用は、多くの患者にとって利用しやすさを制限することで、市場の成長に大きな課題を投げかけています。すべての保険制度が適切な払い戻しを提供するわけではないため、保険適用範囲の相違がこの問題をさらに悪化させています。その結果、患者はより手ごろな代替治療を選択し、関節内補充療法への需要が減少する可能性があります。このような経済的障壁は、医療提供者の間での普及を妨げ、最終的には関節内補充療法市場の全体的な拡大と可能性に影響を与えることになります。

目次

第1章 関節内補充療法の世界市場：イントロダクション

• 市場のイントロダクション
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 関節内補充療法の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 関節内補充療法の世界市場：タイプ別

• 概要
• 単回注射ビスコサプリ療法
• 3回注射ビスコサプリ療法
• 5回注射ビスコサプリ療法

第6章 関節内補充療法の世界市場：用途別

• 概要
• 変形性膝関節症
• 変形性股関節症
• 変形性肩関節症

第7章 関節内補充療法の世界市場：エンドユーザー別

• 概要
• 病院
• 整形外科クリニック/外来手術センター
• 小売薬局

第8章 関節内補充療法の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の関節内補充療法市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第10章 企業プロファイル

• Sanofi
• Anika Therapeutics, Inc.
• Seikagaku Corp.
• Zimmer Biomet
• Smith & Nephew PLC
• Ferring Pharmaceuticals B.V.
• Lifecore Biomedical
• LG Life Sciences Ltd.
• Fidia Farmaceutici S.p.A
• F.Hoffmann-La Roche Ltd.

第11章 付録

• 関連調査

Viscosupplementation Market Valuation- 2024-2031

The Viscosupplementation Market is increasing due to the rising prevalence of osteoarthritis and other joint disorders. Innovations in hyaluronic acid-based products are driving demand, with healthcare providers increasingly adopting these treatments for pain relief and joint function improvement. This is likely to enable the market size to surpass USD 6.5 Billion valued in 2024 to reach a valuation of aroundUSD 12.38 Billion by 2031.

Additionally, the market is seeing growth from the expanding aging population, which is driving the need for non-surgical options. Moreover, increasing awareness about viscosupplementation as a minimally invasive treatment is contributing to its popularity among patients seeking alternatives to traditional joint surgeries. The rising demand for viscosupplementation is enabling the market to grow at aCAGR of 9.24% from 2024 to 2031.

Definition/Overview

Viscosupplementation is a medical treatment involving hyaluronic acid injections into joints, increasing lubrication and cushioning. It is primarily used to manage pain and improve mobility in osteoarthritis patients.

Its use is focused on alleviating joint pain, particularly in the knee, by increasing synovial fluid. This non-surgical option is increasingly popular for managing moderate arthritis cases, driving adoption.

Future scope includes increasing advancements in hyaluronic acid formulations, driving better outcomes. The aging population and increasing demand for non-invasive treatments are contributing to the expanding market potential for viscosupplementation.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How Is the Increasing Prevalence of Osteoarthritis Driving the Growth Of The Viscosupplementation Market?

The increasing prevalence of osteoarthritis significantly drives the growth of the Viscosupplementation market by creating a higher demand for effective pain management solutions. As more individuals seek relief from joint pain and improved mobility, healthcare providers increasingly adopt viscosupplementation treatments. These minimally invasive options offer a viable alternative to surgical interventions, appealing to patients looking for effective yet less invasive approaches. Consequently, this trend supports the expansion of the market overall.

How Does the High Cost of Viscosupplementation Treatments Challenge the Growth of The Market?

The high cost of Viscosupplementation treatments poses a significant challenge to market growth by limiting accessibility for many patients. Insurance coverage discrepancies further exacerbate this issue, as not all plans provide adequate reimbursement. Consequently, patients may opt for alternative, more affordable treatments, reducing demand for viscosupplementation. This financial barrier can hinder widespread adoption among healthcare providers, ultimately impacting the overall expansion and potential of the viscosupplementation market.

Category-wise Acumens

How Will the Increasing Effectiveness of Hyaluronic Acid in Pain Management Drive the Growth of The Hyaluronic Acid-Based Product Segment?

The increasing effectiveness of hyaluronic acid in pain management will drive the growth of the hyaluronic acid-based product segment in the Viscosupplementation Market. Its ability to improve joint lubrication and mobility, particularly in osteoarthritis patients, makes it a preferred treatment option. As more healthcare providers and patients recognize its benefits in offering long-lasting relief without surgery, demand for hyaluronic acid-based products will continue to expand, supporting this segment's growth.

How Will the Growing Preference for Minimally Invasive Procedures Drive the Growth Of The Single Injection Segment?

The growing preference for minimally invasive procedures will drive the growth of the single injection segment in the Viscosupplementation Market. Single injections offer a simpler, less invasive option for osteoarthritis patients, reducing the number of hospital visits and overall discomfort. This convenience appeals to both patients and healthcare providers, enhancing its adoption. As the demand for efficient and patient-friendly treatments increases, the single injection segment is positioned for significant growth.

Country/Region-wise Acumens

Will The High Prevalence of Osteoarthritis and Advanced Healthcare Infrastructure Drive the Dominance of North America in The Viscosupplementation Market?

The high prevalence of osteoarthritis and advanced healthcare infrastructure will drive the dominance of North America in the Viscosupplementation Market. With a significant aging population, the demand for effective pain management solutions is increasing. Moreover, the region's robust healthcare system supports innovation and adoption of new treatments, allowing for better patient outcomes. The presence of leading manufacturers and strong research initiatives further enhances North America's position as a key player in this market.

Will Rising Awareness of Osteoarthritis Treatments Drive the Rapid Growth of The Asia-Pacific Region in The Viscosupplementation Market?

Increasing healthcare expenditures and rising awareness of osteoarthritis treatments will drive the rapid growth of the Asia-Pacific region in the viscosupplementation market. As more individuals become aware of effective pain management options, demand for these therapies is expected to rise. Improved healthcare infrastructure facilitates access to innovative treatments, making them more widely available. Additionally, the growing aging population in this region further contributes to the increasing need for viscosupplementation solutions, supporting market expansion.

Competitive Landscape

The viscosupplementation market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the viscosupplementation market include:

Sanofi S.A.

Anika Therapeutics, Inc.

Seikagaku Corporation

Zimmer Biomet Holdings Inc.

Smith & Nephew PLC

Ferring Pharmaceuticals B.V.

Lifecore Biomedical

Fidia Farmaceutici S.p.A.

Bioventus LLC

Johnson & Johnson Services, Inc.

Latest Developments

In September 2024, Sanofi S.A. announced a licensing agreement with RadioMedix and Orano Med for a next-generation radioligand medicine aimed at treating rare cancers, showcasing its commitment to innovative cancer therapies.

In March 2023, Seikagaku Corporation launched Hyalgan G-F 20 in Japan, a new formulation of hyaluronic acid designed for knee osteoarthritis, enhancing its product portfolio in the viscosupplementation market.

In April 2023, Zimmer Biomet Holdings Inc. received FDA 510(k) clearance for their Persona Knee Hyaluronic Acid, which is intended to provide pain relief for patients suffering from knee osteoarthritis, reflecting their focus on advancing treatment options.

In October 2023, Anika Therapeutics, Inc. reported positive results from a Phase 3 study of Qsymia, aimed at alleviating knee osteoarthritis pain, reinforcing its position in the development of effective non-surgical treatments for joint pain.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VISCOSUPPLEMENTATION MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL VISCOSUPPLEMENTATION MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL VISCOSUPPLEMENTATION MARKET, BY TYPE

• 5.1 Overview
• 5.2 Single Injection Viscosupplementation
• 5.3 Three Injection Viscosupplementation
• 5.4 Five Injection Viscosupplementation

6 GLOBAL VISCOSUPPLEMENTATION MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Knee Osteoarthritis
• 6.3 Hip Osteoarthritis
• 6.4 Shoulder Osteoarthritis

7 GLOBAL VISCOSUPPLEMENTATION MARKET, BY END-USER

• 7.1 Overview
• 7.2 Hospitals
• 7.3 Orthopedic Clinics/ Ambulatory Surgical Centers
• 7.4 Retail Pharmacies

8 GLOBAL VISCOSUPPLEMENTATION MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL VISCOSUPPLEMENTATION MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Sanofi
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Anika Therapeutics, Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Seikagaku Corp.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Zimmer Biomet
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Smith & Nephew PLC
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Ferring Pharmaceuticals B.V.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Lifecore Biomedical
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 LG Life Sciences Ltd.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Fidia Farmaceutici S.p.A
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 F.Hoffmann-La Roche Ltd.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research